Skip to main content
SpringerLink
Log in

Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R, Svoboda J (2013) Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 88(10):890–894

    Article  CAS  Google Scholar 

  2. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY (2017) Axicabtagene ciloleucel car t-cell therapy in refractory large b-cell lymphoma. N Engl J Med 377(26):2531–2544

    Article  CAS  Google Scholar 

  3. International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994

    Article  Google Scholar 

  4. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 131(2):193–200

    Article  CAS  Google Scholar 

  5. Yim SK, Yhim HY, Han YH, Jeon SY, Lee NR, Song EK, Jeong HJ, Kim HS, Kwak JY (2019) Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index. Ann Hematol 98(12):2739–2748

    Article  CAS  Google Scholar 

  6. Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkinlymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 201;6(1): e12-e19

  7. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A (2019) Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, Phase II Study. J Clin Oncol 37(6):481–489

    Article  CAS  Google Scholar 

  8. Zhang R, Deng Q, Jiang YY, Zhu HB, Wang J, Zhao MF (2019) Effect and changes in PD-1 expression of CD19 CAR-T cells from T cells highly expressing PD-1 combined with reduced-dose PD-1 inhibitor. Oncol Rep 41(6):3455–3463

    CAS  PubMed  Google Scholar 

  9. Funk CR, Petersen CT, Jagirdar N, et al. Oligoclonal T cells transiently expand and express Tim-3 and PD-1 following anti-CD19 CAR T cell therapy: a case report. Int J Mol Sci. 2018;19(12)

Download references

Funding

This study was financially supported by the National Natural Science Foundation of China (81900202, for ZL) and the Fundamental Research Funds for the Central Universities (3332018036, for ZL).

Author information

Authors and Affiliations

  1. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    Lu Zhang, Wei Zhang & Daobin Zhou

Authors
  1. Lu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daobin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daobin Zhou.

Ethics declarations

Informed consent was obtained from our patient. This study was performed in accordance with the ethical standards provided in the 1964 Declaration of Helsinki and its later amendments.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Lu Zhang is the first author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Zhang, W. & Zhou, D. Long-term treatment response to PD-1 blockade therapy in a patient with DLBCL relapsed after anti-CD19 chimeric antigen receptor T cell treatment. Ann Hematol 100, 289–291 (2021). https://doi.org/10.1007/s00277-020-03993-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03993-9

Search

Navigation